/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Event: ESC Congress 2019
Topic: Antidiabetic Pharmacotherapy
Session: New frontiers: SGLT2 inhibitors in cardiorenal disease
ESC 365 is supported by
